# Bicara Therapeutics

Bicara Therapeutics is an Asset Manager based in Cambridge, United States.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** Cambridge, MA, United States
- **Founded:** 2018
- **Assets under management:** Undisclosed
- **Website:** bicara.com

## Regulatory record

- **Reports private funds:** No

## About

Bicara Therapeutics launched in 2018, co-founded by Biocon executive Kiran Mazumdar-Shaw and a team of immuno-oncology researchers, with Rachel Salius assuming the CEO role in 2021 (per Fierce Biotech, 2021). The firm operates as a clinical-stage biotechnology company, not a traditional family office or allocator — its capital is venture-funded, and its structure is designed to advance a novel bifunctional antibody platform through Phase 2/3 trials. Biocon remains a strategic backer, providing both financial and manufacturing support, while a syndicate of life sciences investors including Red Tree Venture Capital and others have participated in its funding rounds. The firm's strategy concentrates exclusively on developing ficerafusp alfa (BCA101), a first-in-class bifunctional fusion protein that simultaneously inhibits EGFR and sequesters TGF-beta within the tumor microenvironment. Clinical trials target recurrent/metastatic head and neck squamous cell carcinoma, with Phase 2 dose-expansion data expected to inform a potential registrational path. Bicara does not operate a diversified pipeline; the model hinges on demonstrating statistically significant overall response rates in a well-defined patient population, then partnering or commercializing. The geographic scope is US-centric for clinical operations, with Biocon's Bangalore infrastructure providing manufacturing and early-stage development support. Bicara has raised over $150 million in disclosed venture financing, most recently closing an oversubscribed Series C in 2023 (per Endpoints News, March 2023). The firm operates from Cambridge, Massachusetts, with a lean team focused on clinical operations, regulatory strategy, and biostatistics rather than large in-house discovery. Its board includes investors from RA Capital Management and Biocon. March 2023: Closed a $108 million Series C financing to fund the ongoing Phase 2 trial of ficerafusp alfa in head and neck cancer (per Endpoints News, March 2023). Bicara's structural distinction lies in its India-to-US clinical execution axis. Unlike most US biotechs that outsource manufacturing contractually, Bicara leverages Biocon's large-scale biologics manufacturing capability as both an equity backer and a production partner — creating a hybrid cost structure that reduces burn rate during clinical development. This is not a fund, not a family office, and not a platform company: it is a single-candidate bet with an industrial partner deeply embedded in its capitalization and supply chain.

## Sectors

- Biotechnology
- Oncology

## Questions

### How does Bicara's relationship with Biocon shape its business model?

Biocon, the Indian biopharmaceutical major, co-founded Bicara and provides both equity backing and large-scale biologics manufacturing through its Bangalore facilities. This arrangement gives Bicara an integrated supply chain without the capital expenditure of building its own plant, lowering the cost of clinical production relative to peers who rely on contract development and manufacturing organizations.

### Does Bicara Therapeutics operate any other pipeline programs?

No. Bicara is effectively a single-asset company, with all disclosed resources directed toward ficerafusp alfa's clinical development. The firm has not announced preclinical programs or platform extensions, focusing exclusively on advancing one molecule through Phase 2 and toward a potential biologics license application.

### What is the firm's current clinical trial status?

As of the most recent public disclosures, ficerafusp alfa is in a Phase 2 dose-expansion study for recurrent/metastatic head and neck squamous cell carcinoma. The trial is evaluating overall response rate and durability of response, with data expected to inform whether the program advances to a registrational Phase 3 or pivotal study.

## Related profiles

- [National Vision Holdings](https://altss.com/profile/national-vision-holdings-inc)
- [Marten Transport](https://altss.com/profile/marten-transport-ltd)

---

Last updated: 2026-06-28T22:09:38.149Z

Canonical page: https://altss.com/profile/bicara-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology